MedTrace Logo

Identification and Treatment of the Liability to Develop Schizophrenia

NCT00305474 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2009-06-24

No results posted yet for this study

Summary

This study seeks to determine whether adult, non-psychotic, first-degree relatives of schizophrenic patients who show specific neurocognitive deficits and negative symptoms will show improvements in these areas following a 6-month, double-blind trial of a low dose (up to 2.0 mg) of risperidone.

Conditions

Interventions

DRUG

Risperidone

Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients

Sponsors & Collaborators

  • Ortho-McNeil Janssen Scientific Affairs, LLC

    collaborator INDUSTRY

  • Central South University

    lead OTHER

Principal Investigators

  • William Stone, PhD · Harvard Medical School (HMS and HSDM)

  • Lingjiang Li, MD, PhD · Central South Unversity

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2010-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00305474 on ClinicalTrials.gov